Bangyun Medical Closes Nearly 100 Million Yuan Angel Round Led by Dalton Venture, Accelerating Upgrading and Global Innovation in Advanced Wound Closure | Dalton News

Background

Recently, Shanghai Bangyun Medical Technology Co., Ltd. (hereinafter referred to as "Bangyun Medical") announced the completion of a nearly RMB 100 million angel round of financing, led by Dalton Venture. The funds will be primarily used for: capacity expansion of high-end products such as absorbable barbed sutures and antibacterial sutures, as well as tackling domestic raw material supply chain independence; development and clinical trials of BESTURE, a globally first-of-its-kind product for accelerating wound healing; and expansion of professional sales and market operations teams.

The following is reprinted from VBData.

Founded in 2019, Shanghai Bangyun Medical Technology Co., Ltd. focuses on the R&D, production, and sales of high-end wound closure consumables and devices for surgical procedures. Its products cover general surgery, gynecology, urology, plastic surgery, and other clinical departments. The company is committed to providing high-quality wound closure solutions for medical professionals and patients through localized compliant production and clinically driven innovation.

01

Breaking Foreign Monopolies: A Top-Tier "Industry + Academia" Team Tackles High-End Wound Closure

Surgical sutures are indispensable products in the medical field, widely used in various surgical procedures including open surgery, minimally invasive surgery, specialized operations, as well as wartime, disaster, and trauma treatment scenarios. According to Frost & Sullivan data, China's surgical suture market is expected to reach RMB 8.6 billion by 2026 and surpass RMB 10 billion by 2030, making it one of the largest single-product markets in the minimally invasive surgery field. The accelerating aging population, steady growth in total surgical volume, increasing adoption of minimally invasive procedures, and expansion of primary healthcare capabilities together form the rigid demand foundation for this market's long-term growth.

Among these, high-end functional products such as absorbable and knotless barbed sutures are leading the industry with growth rates approximately 3-4 times that of traditional sutures, with their market share continuing to rise. However, for a long time, over 70% of the high-end market in this sector has been monopolized by foreign brands such as Johnson & Johnson, while domestic brands have mostly concentrated on the mid-to-low-end segment, with core technologies and supply chains long constrained by foreign players. Nevertheless, driven by four core forces — normalized centralized procurement, domestic technological breakthroughs, upgraded clinical demands, and tightened industry compliance — the surgical suture market is undergoing deep restructuring, presenting a new landscape of domestic high-end breakthroughs, structural tilt toward innovation, and competition shifting toward value-based comparison.

Against this backdrop, Bangyun Medical has achieved breakthrough through a differentiated product portfolio. Its core developed product, Weijia® Absorbable Knotless Barbed Suture, requires no knot-tying and degrades within the body, adapting to tissue closure scenarios in minimally invasive surgeries such as laparoscopy, effectively shortening operative time and reducing intraoperative bleeding. Building on this, the company has achieved the leap from supply chain development to independent innovation: a proprietary triclosan antibacterial suture production process that achieves long-lasting, stable drug release on par with imported competitors at equivalent content standards, avoiding the clinical pain point of excessive tissue reaction. Additionally, Bangyun Medical's globally first-of-its-kind absorbable self-powering suture (BESTURE), jointly developed with a professor team from Donghua University, generates electric field stimulation through movement and can accelerate wound healing by 50%. Related research findings were published in the international top-tier academic journal Nature Communications in 2024.

This outstanding technological innovation capability stems from the company's top-tier core management team and interdisciplinary R&D team. Chairman and General Manager Jin Su previously worked at Johnson & Johnson for 14 years and served as President of B. Braun China for 10 years, possessing deep international perspective and management integration capabilities. The company's executives in production, marketing, and R&D have backgrounds in foreign enterprise industrial management and top-tier academic experience, while relying on an interdisciplinary development team composed of doctoral supervisors, materials science PhDs, and clinical physicians to safeguard the entire chain from product R&D and production to commercialization.

02

Full-Line Centralized Procurement Wins and Dual Recognition from Global Giants Accelerate Commercialization

Leveraging the policy opportunity of national centralized volume-based procurement of medical consumables, Bangyun Medical has rapidly broken through in the market. In the recent 24-province (municipality, autonomous region, and corps) inter-provincial alliance centralized procurement for sutures led by Liaoning, Bangyun Medical's full range of suture products were successfully selected, and in the core barbed suture category it ranked in the first tier, obtaining qualifications for secondary allocation and free-volume distribution, covering a vast market of over 800 million people nationwide. This is expected to significantly enhance the market penetration and clinical accessibility of domestic high-end knotless barbed sutures.

Beyond breakthroughs in the domestic market, Bangyun Medical has also earned high recognition from global medical giant Medtronic through its independent production processes and ISO13485 quality system certified by TÜV SÜD. Medtronic's subsidiary Covidien and Bangyun Medical have officially launched the "Suture for Future" surgical suture strategic cooperation project, reaching a capacity cooperation intention at the million-unit level, marking Bangyun Medical's formal entry into a new stage of international collaborative innovation, with domestic high-end sutures gradually advancing toward the global market.

03

Investor Perspective

Dalton Venture stated: "The inclusion of sutures in national centralized volume-based procurement of medical consumables has accelerated the dismantling of long-standing foreign monopolies, creating a golden window for domestic substitution for quality domestic enterprises with production operational efficiency, marketing strategy, and clinical innovation capabilities. Bangyun Medical possesses a combination of 'industry giant leaders and academic leaders,' demonstrating not only strong commercialization execution and breakthrough capabilities amid procurement reform, but also leading hard-core strength in underlying polymer material processes and innovative electromechanical suture technology. We are very optimistic about Bangyun Medical's potential to lead in the high-end wound closure field, and will continue to empower the company's growth, helping to promote the scaled, high-end upgrading of China's medical consumables industry."

04

Founder's Vision

Bangyun Medical Chairman Jin Su stated: "We are deeply grateful for Dalton Venture's high recognition of and steadfast support for Bangyun Medical. Following this financing round, we will fully launch Bangyun Anhui's second production base and capacity expansion project, completing scaled production capabilities for our innovation pipeline; simultaneously, we will deepen industry-university-research collaboration, committed to打通核心原材的国产化供应链, and fully advance clinical trials and commercialization of the BESTURE innovative product. Bangyun Medical will always uphold the vision of 'Reliable and Accessible, Serving More Patients,' adhere to clinical orientation, and strive to become a leading benchmark in China's domestic wound closure field."

---

ID: daltonventure

Long press to follow